Werewolf Therapeutics Inc (NASDAQ:HOWL)’s traded shares stood at 3.85 million during the last session, with the company’s beta value hitting 0.51. At the close of trading, the stock’s price was $3.40, to imply a decrease of -6.34% or -$0.23 in intraday trading. The HOWL share’s 52-week high remains $8.19, putting it -140.88% down since that peak but still an impressive 53.82% since price per share fell to its 52-week low of $1.57. The company has a valuation of $148.58M, with an average of 2.3 million shares in intraday trading volume over the past 10 days and average of 436.87K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Werewolf Therapeutics Inc (HOWL), translating to a mean rating of 1.00. Of 4 analyst(s) looking at the stock, 0 analyst(s) give HOWL a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.41.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Werewolf Therapeutics Inc (NASDAQ:HOWL) trade information
After registering a -6.34% downside in the last session, Werewolf Therapeutics Inc (HOWL) has traded red over the past five days. The 5-day price performance for the stock is 65.05%, and 67.49% over 30 days. With these gigs, the year-to-date price performance is -11.92%. Short interest in Werewolf Therapeutics Inc (NASDAQ:HOWL) saw shorts transact 1.04 million shares and set a 7.94 days time to cover.
The extremes give us $12 and $12 for target low and target high price respectively. As such, HOWL has been trading -252.94% off suggested target high and -252.94% from its likely low.
Werewolf Therapeutics Inc (HOWL) estimates and forecasts
Looking at statistics comparing Werewolf Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Werewolf Therapeutics Inc (HOWL) shares are -46.79% down over the last 6 months, with its year-to-date growth rate lower than industry average at -55.24% against 17.40%. Revenue is forecast to shrink -78.30% this quarter before falling -36.40% for the next one. The rating firms project that company’s revenue will shrink -82.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 710k. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 1.15M.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -13.31% for the past 5-year period. While 2024 is set for a -53.81% return in earnings, projections for the next 5 years are at 10.90% annually.
HOWL Dividends
Werewolf Therapeutics Inc has its next earnings report out on 2024-Aug-08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is MPM ASSET MANAGEMENT LLC with 4.28 million shares, or about 10.2967% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $10.45 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Werewolf Therapeutics Inc (HOWL) shares. Going by data provided on Jun 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 702.54 shares. This is just over 1.61% of the total shares, with a market valuation of $2.39 million. Data from the same date shows that the other fund manager holds a little less at 684.3, or 1.57% of the shares, all valued at about 2.33 million.
